10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

BioMimetic Therapeutics Inc. (BMTI) President and CEO Samuel Eugene Lynch sells 6,000 Shares

December 16, 2009 | About:
insider

insider

57 followers
President and CEO of BioMimetic Therapeutics Inc. (BMTI) Samuel Eugene Lynch sells 6,000 shares of BMTI on 12/15/2009 at an average price of $12.18 a share.

BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) as its primary technology platform. This molecule is a synthetic copy of one of the body's principal agents to stimulate and direct healing and regeneration. The mechanism of action of this platform technology suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine. Additionally, BioMimetic Therapeutics has completed and ongoing clinical trials with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. Biomimetic Therapeutics Inc. has a market cap of $260 million; its shares were traded at around $11.93 with and P/S ratio of 82.6.

This is the annual revenues and earnings per share of BMTI over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of BMTI.


CEO Recent Trades:



  • Sell:: President and CEO Samuel Eugene Lynch sold 6,000 shares of BMTI stock on 12/03/2009 at the average price of 11.09, the price of the stock has increased by 7.57% since
  • Sell:: President and CEO Samuel Eugene Lynch sold 6,000 shares of BMTI stock on 11/17/2009 at the average price of 11.72, the price of the stock has increased by 1.79% since
  • Sell:: President and CEO Samuel Eugene Lynch sold 6,000 shares of BMTI stock on 11/05/2009 at the average price of 11.67, the price of the stock has increased by 2.23% since
  • Sell:: President and CEO Samuel Eugene Lynch sold 9,000 shares of BMTI stock on 10/21/2009 at the average price of 14.03, the price of the stock has decreased by 14.97% since
  • Sell:: President and CEO Samuel Eugene Lynch sold 7,500 shares of BMTI stock on 10/06/2009 at the average price of 12.14, the price of the stock has decreased by 1.73% since



This is the insider trade history vs. stock price of BMTI. For the complete insider trading history of BMTI, click here.




Directors and Officers Recent Trades:



  • Buy:: Director James G Murphy bought 508 shares of BMTI stock on 06/25/2009 at the average price of 8.5, the price of the stock has increased by 40.35% since
  • Buy:: 10% Owner A/s Novo bought 343,406 shares of BMTI stock on 06/25/2009 at the average price of 8.5, the price of the stock has increased by 40.35% since
  • Buy:: Director Gary E Friedlaender bought 8,174 shares of BMTI stock on 06/25/2009 at the average price of 8.5, the price of the stock has increased by 40.35% since


  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership

About the author:

insider
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 5.0/5 (2 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK